Literature DB >> 25337244

Expression of Yes-associated protein (YAP) in breast phyllodes tumor.

Sang Kyum Kim1, Woo Hee Jung1, Ja Seung Koo1.   

Abstract

This study aimed to identify expression profiles of Yes-associated protein (YAP) and its phosphorylated form (pYAP) in phyllodes tumor (PT) of human breast and verify the clinical implications. We selected PTs from the pathologic archive and reviewed the histologic features (141 benign, 27 borderline, and 15 malignant). We made tissue microarray (TMA) block from the formalin-fixed paraffin-embedded (FFPE) tissue corresponding to the representative section. Using TMA block, we performed immunohistochemical staining of YAP and pYAP. In the stromal component, expressions of YAP and pYAP were increased in borderline/malignant PT with comparison of benign PT (P = 0.002, and P < 0.001, respectively). In the epithelial component, cytoplasmic expression of YAP was highest in borderline PT (P = 0.001). Stromal YAP expression (P < 0.001) and stromal pYAP expression (P = 0.042) were associated with shorter disease-free survival (DFS) and stromal pYAP expression (P = 0.001) was associated with shorter overall survival (OS) in univariate Cox analysis. In multivariate Cox analysis, stromal YAP expression was an independent prognostic factor associated with shorter DFS (Hazard ration: 3.206, 95% CI: 1.000-10.27, P = 0.050). In conclusion, expression level of YAP in stromal component was increased along with histologic grade of PT and YAP expression in PT was related to tumor progression and poor prognosis.

Entities:  

Keywords:  Breast; YAP; phyllodes tumor

Mesh:

Substances:

Year:  2014        PMID: 25337244      PMCID: PMC4203215     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  20 in total

1.  A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator.

Authors:  R Yagi; L F Chen; K Shigesada; Y Murakami; Y Ito
Journal:  EMBO J       Date:  1999-05-04       Impact factor: 11.598

2.  BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma.

Authors:  J H Hsu; E R Lawlor
Journal:  Oncogene       Date:  2010-12-20       Impact factor: 9.867

3.  Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon.

Authors:  Michael Overholtzer; Jianmin Zhang; Gromoslaw A Smolen; Beth Muir; Wenmei Li; Dennis C Sgroi; Chu-Xia Deng; Joan S Brugge; Daniel A Haber
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-07       Impact factor: 11.205

4.  Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer.

Authors:  Yang Wang; Qianze Dong; Qingfu Zhang; Zixuan Li; Enhua Wang; Xueshan Qiu
Journal:  Cancer Sci       Date:  2010-01-23       Impact factor: 6.716

5.  MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties.

Authors:  Angela M Liu; Ronnie T P Poon; John M Luk
Journal:  Biochem Biophys Res Commun       Date:  2010-03-10       Impact factor: 3.575

6.  YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas.

Authors:  Zofia Hélias-Rodzewicz; Gaëlle Pérot; Frédéric Chibon; Céline Ferreira; Pauline Lagarde; Philippe Terrier; Jean-Michel Coindre; Alain Aurias
Journal:  Genes Chromosomes Cancer       Date:  2010-12       Impact factor: 5.006

7.  Phyllodes tumors of the breast: a case series of 106 patients.

Authors:  Jamel Ben Hassouna; Tarak Damak; Amor Gamoudi; Riadh Chargui; Fethi Khomsi; Slim Mahjoub; Maher Slimene; Tarak Ben Dhiab; Monia Hechiche; Hamouda Boussen; Khaled Rahal
Journal:  Am J Surg       Date:  2006-08       Impact factor: 2.565

8.  Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis.

Authors:  Subham Basu; Nicholas F Totty; Meredith S Irwin; Marius Sudol; Julian Downward
Journal:  Mol Cell       Date:  2003-01       Impact factor: 17.970

9.  Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer.

Authors:  Woojin Jeong; Sang-Bae Kim; Bo Hwa Sohn; Yun-Yong Park; Eun Sung Park; Sang Cheol Kim; Sung Soo Kim; Randy L Johnson; Michael Birrer; David S L Bowtell; Gordon B Mills; Anil Sood; Ju-Seog Lee
Journal:  Anticancer Res       Date:  2014-02       Impact factor: 2.480

10.  Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach.

Authors:  Lars Zender; Mona S Spector; Wen Xue; Peer Flemming; Carlos Cordon-Cardo; John Silke; Sheung-Tat Fan; John M Luk; Michael Wigler; Gregory J Hannon; David Mu; Robert Lucito; Scott Powers; Scott W Lowe
Journal:  Cell       Date:  2006-06-30       Impact factor: 41.582

View more
  5 in total

1.  In phyllodes tumors of the breast expression of SPARC (osteonectin/BM40) mRNA by in situ hybridization correlates with protein expression by immunohistochemistry and is associated with tumor progression.

Authors:  Nah Ihm Kim; Ga-Eon Kim; Ji Shin Lee; Min Ho Park
Journal:  Virchows Arch       Date:  2016-12-01       Impact factor: 4.064

Review 2.  Dual roles of yes-associated protein (YAP) in colorectal cancer.

Authors:  Chunlin Ou; Zhenqiang Sun; Shen Li; Guiyuan Li; Xiayu Li; Jian Ma
Journal:  Oncotarget       Date:  2017-08-11

3.  The prognostic value of YAP1 on clinical outcomes in human cancers.

Authors:  Ying Wu; Yanshen Hou; Peng Xu; Yujiao Deng; Kang Liu; Meng Wang; Tian Tian; Cong Dai; Na Li; Qian Hao; Dingli Song; Ling Hui Zhou; Zhijun Dai
Journal:  Aging (Albany NY)       Date:  2019-10-15       Impact factor: 5.682

4.  Expression characteristics of the yes-associated protein in breast cancer: A meta-analysis.

Authors:  Lan Li; Jin Luo; Jing-Yi Fang; Rui Zhang; Jian-Bo Ma; Zheng-Peng Zhu
Journal:  Medicine (Baltimore)       Date:  2022-08-26       Impact factor: 1.817

Review 5.  Phyllodes Tumors: A Scoping Review of the Literature.

Authors:  Jessica Bogach; Saad Shakeel; Frances C Wright; Nicole J Look Hong
Journal:  Ann Surg Oncol       Date:  2021-07-22       Impact factor: 5.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.